Oric Pharmaceuticals 

Yahoo Finance • 2 hours ago

Stocks Settle Higher on Hopes for Conclusion to Iran War

The S&P 500 Index ($SPX) (SPY) on Wednesday closed up +0.72%, the Dow Jones Industrial Average ($DOWI) (DIA) closed up +0.48%, and the Nasdaq 100 Index ($IUXX) (QQQ) closed up +1.18%.  June E-mini S&P futures (ESM26) rose +0.74%, and June... Full story

Yahoo Finance • 7 hours ago

Stocks Climb on War-End Optimism

The S&P 500 Index ($SPX) (SPY) today is up +0.97%, the Dow Jones Industrial Average ($DOWI) (DIA) is up +0.86%, and the Nasdaq 100 Index ($IUXX) (QQQ) is up +1.45%.  June E-mini S&P futures (ESM26) are up +0.96%, and June E-mini Nasdaq fut... Full story

Yahoo Finance • 9 hours ago

Stocks Rally on Optimism that the War in Iran is Near a Conclusion

The S&P 500 Index ($SPX) (SPY) today is up +0.52%, the Dow Jones Industrial Average ($DOWI) (DIA) is up +0.43%, and the Nasdaq 100 Index ($IUXX) (QQQ) is up +0.68%.  June E-mini S&P futures (ESM26) are up +0.57%, and June E-mini Nasdaq fut... Full story

Yahoo Finance • 11 hours ago

Wall Street Set to Open Higher as Trump Says US Will Consider Ceasefire if Hormuz Strait Opened

US stocks looked set to open higher in Wednesday's trading session after President Trump claimed tha PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 26 days ago

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, March 06, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance,... Full story

Yahoo Finance • last month

Oric Pharmaceuticals price target raised to $25 from $23 at H.C. Wainwright

H.C. Wainwright analyst Robert Burns raised the firm’s price target on Oric Pharmaceuticals (ORIC) to $25 from $23 and keeps a Buy rating on the shares. The firm, which is pulling its valuation forward, says it expects the next 12 months t... Full story

Yahoo Finance • last month

ORIC Pharmaceuticals GAAP EPS of -$0.30 beats by $0.06

* ORIC Pharmaceuticals press release [https://seekingalpha.com/pr/20409735-oric-pharmaceuticals-reports-fourth-quarter-and-full-year-2025-financial-results-and] (ORIC [https://seekingalpha.com/symbol/ORIC]): Q4 GAAP EPS of -$0.30 beats b... Full story

Yahoo Finance • 4 months ago

ORIC® Pharmaceuticals Presents Potential Best-in-Class Profile for Enozertinib with Robust Systemic and CNS Activity in 1L and 2L NSCLC Patients with EGFR Exon 20 Mutations at the ESMO Asia Congress 2025

Highly differentiated 1L preliminary systemic activity of 67% ORR and 100% intracranial ORR (by BICR-RANO), including in patients with active brain metastases 45% ORR in 2L patients exceeds competitor benchmarks Competitive safety profil... Full story

Yahoo Finance • 4 months ago

ORIC® Pharmaceuticals Presents Enozertinib Data in NSCLC Patients with HER2 Exon 20 Mutations at the ESMO Asia Congress 2025

Systemic activity of 35% ORR in 2L+ patients, including in patients with active brain metastases Manageable safety profile with low discontinuation rate Enrollment completed; no further development planned in this patient population Com... Full story

Yahoo Finance • 4 months ago

ORIC® Pharmaceuticals Presents Potential Best-in-Class Profile for Enozertinib with Robust Systemic and CNS Activity in 1L and Previously Treated NSCLC Patients with EGFR Atypical Mutations at the ESMO Asia Congress 2025

Highly differentiated 1L EGFR PACC preliminary systemic activity of 80% ORR and 100% intracranial ORR, including in patients with active brain metastases 36% ORR in median 3L EGFR PACC patients exceeds competitor benchmarks Competitive s... Full story

Yahoo Finance • 4 months ago

ORIC® Pharmaceuticals Announces Enozertinib (ORIC-114) Late-Breaking Oral Presentations in EGFR Atypical and EGFR exon 20 NSCLC at the ESMO Asia Congress 2025

SOUTH SAN FRANCISCO and SAN DIEGO, Dec. 03, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today a... Full story

Yahoo Finance • 4 months ago

ORIC® Pharmaceuticals to Participate in the 8th Annual Evercore Healthcare Conference

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Nov. 24, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance,... Full story

Yahoo Finance • 5 months ago

ORIC® Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Clinical and Operational Updates

Announced completion of dose exploration portion of ORIC-944 Phase 1b clinical trial and presented data that continues to demonstrate potential best-in-class efficacy and safety Bolstered leadership team with the appointment of Kevin Brod... Full story

Yahoo Finance • 5 months ago

ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Nov. 04, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance,... Full story

Yahoo Finance • 5 months ago

ORIC® Pharmaceuticals Presented Preclinical Data at the EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics Supporting Best-in-Class Potential of ORIC-944 to Treat Patients With Prostate Cancer and Other Solid Tumors

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Oct. 27, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance,... Full story

Yahoo Finance • 7 months ago

ORIC® Pharmaceuticals Expands Leadership Team with the Appointment of Kevin Brodbeck as Chief Technical Officer

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Aug. 18, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance,... Full story

Yahoo Finance • 9 months ago

Ladenburg Thalmann initiates ORIC Pharmaceuticals stock with Buy rating

Investing.com - Ladenburg Thalmann initiated coverage on ORIC Pharmaceuticals (NASDAQ:ORIC) with a Buy rating and a $15.00 price target on Tuesday. Currently trading at $10.65, the stock has significant upside potential, with analyst targe... Full story

Yahoo Finance • 9 months ago

Oric Pharmaceuticals director You Angie buys $262,898 in stock

Director You Angie of Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) recently purchased a total of $262,898 in company stock. According to a Form 4 filing with the Securities and Exchange Commission, the purchases were made in two transactions a... Full story

Yahoo Finance • 10 months ago

JPMorgan biotech/pharma analysts hold analyst/industry conference call

US SMid Biotech Analyst Rama and US Major & Specialty Pharmaceuticals Analyst Schott, along with Dr. Charles Ryan, Genitourinary Medical Oncologist at Memorial Sloan Kettering Cancer Center discuss the evolving treatment landscape in prost... Full story

Yahoo Finance • 10 months ago

Oric Pharmaceuticals files to sell 19.23M shares of common stock by selling shareholders

* Oric Pharmaceuticals (NASDAQ:ORIC [https://seekingalpha.com/symbol/ORIC]) filed a prospectus to resale 19.23M shares of common stock. * The company will not receive any proceeds from the sale of ordinary shares by the selling shareho... Full story